Related Experiment Videos
Gene stereotactic neurosurgery for recurrent malignant gliomas
F Colombo1, M Zanusso, L Casentini
1Department of Neurosurgery, City Hospital, Vicenza, Italy.
Stereotactic and Functional Neurosurgery
|January 1, 1997
Summary
This study explored a gene therapy-immunotherapy protocol for recurrent glioblastoma, showing it was safe and had a clear oncolytic effect. The treatment involved engineered cells and ganciclovir, confirming successful gene transduction.
Area of Science:
- Oncology
- Gene Therapy
- Immunotherapy
Background:
- Glioblastoma recurrence presents significant treatment challenges.
- Novel therapeutic strategies are crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the safety and efficacy of a combined gene therapy-immunotherapy protocol for recurrent glioblastoma.
- To assess the oncolytic effect and gene transduction in patients with recurrent glioblastoma.
Main Methods:
- Intratumoral injection of cells producing a retroviral vector expressing interleukin-2 and herpes simplex virus thymidine kinase.
- Subsequent treatment with ganciclovir in four patients with recurrent glioblastoma.
Main Results:
- Anatomopathological and immunohistochemical analyses confirmed successful gene transduction.
- The combined therapy demonstrated a clear, albeit short-range, oncolytic effect in patients.
Conclusions:
- The gene therapy-immunotherapy protocol is safe for treating recurrent glioblastoma.
- This approach shows potential as an effective treatment strategy for glioblastoma recurrence.